Three Cancer Medicines Green-Lighted in Europe
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended that marketing authorizations be approved for three new cancer drugs: Datroway (datopotamab deruxtecan) to treat advanced breast cancer, Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer, and Dyrupeg (pegfilgrastim) for neutropenia following chemotherapy…
Read More
0
